For employers, focusing solely on medical costs misses a big part of the picture
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
Force Factor Glutathione can help counteract the harmful effects of free radicals by neutralizing them and reducing the risk of cellular damage
Serums have a lighter molecular structure that allows active ingredients to penetrate more deeply into the skin rather than sitting on the surface
CMS indicated that patients with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH are excluded from the Bridge because those are currently Part D-coverable indications